Ceribell is a revolutionary medical device start-up company founded by two faculty members at Stanford University in 2014. Frustrated by the limitations of conventional EEG systems, they developed a point-of-care EEG system to meet clinical unmet needs and make neurological diagnosis more efficient. The company's mission is to make EEG widely accessible, efficient, and cost-effective in order to enhance the diagnosis and treatment of seizure-prone patients.

Ceribell offers an FDA-cleared EEG system called Clarity TM, which eliminates the need for a lengthy setup or waiting for a specialist to interpret initial results. With easy setup that can be performed by any clinician within minutes, Ceribell provides 24/7 continuous bedside EEG monitoring and alerts. Real-time monitoring enables swift and accurate treatment of patients with seizures, leading to improved outcomes and significant cost savings.

Driven by a dynamic leadership team and a culture of innovation, Ceribell is committed to transforming the field of neurology. For more information, please visit their website or contact their dedicated support team